Arvinas Announces Changes to its Board of Directors
NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Liam Ratcliffe, M.D., Ph.D. has stepped d…
Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Lisa Sinclair has joined the company as …
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended …
Arvinas Appoints John Northcott as Chief Commercial Officer
NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in …
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside…
Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
— In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – — Global nomination deadline of August 1, 2022 — NEW HAVEN…
Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
NEW HAVEN, Conn., May 05, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended Ma…
Arvinas to Present at Bank of America Securities 2022 Healthcare Conference
NEW HAVEN, Conn., May 03, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside …
Arvinas to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it will participate in two upcoming virt…
Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
NEW HAVEN, Conn., Feb. 28, 2022 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and fu…
